Answers in CME

CME in Minutes: Education in Oncology & Hematology

Science EN ↓ 140 episodes

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access...

Author

Answers in CME

Episodes

Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer 31.12.2024 14:25

Please visit answersincme.com/EYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses approved and emerging TROP2-directed ADCs for the treatment of HR-positive, HER2-negative/low advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationa...

Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk 27.12.2024 19:19

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better...

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers 17.12.2024 14:11

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants sho...

Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types 13.12.2024 15:03

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Iden...

David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC 12.12.2024 0:31

Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story....

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs 02.12.2024 33:10

Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective...

David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC 26.11.2024 23:57

Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective...

David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC 20.11.2024 31:02

Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participan...

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs 15.11.2024 26:31

Please visit answersincme.com/860/93496951-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the clinical implications of the latest data for HER2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (AD...

Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment 15.11.2024 19:09

Please visit answersincme.com/BHU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lymphoma discusses the treatment landscape for CD30-positive peripheral T-cell lymphoma (PTCL). Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations for frontline trea...

Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice 06.11.2024 15:35

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recomm...

Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs 30.10.2024 27:05

Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the t...

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma 28.10.2024 13:42

Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemi...

Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care 28.10.2024 17:10

Please visit answersincme.com/TBY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in colorectal cancer discuss management of patients with metastatic disease in the third line and beyond. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatme...

Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens 19.09.2024 14:24

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the tr...

Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease 19.09.2024 14:37

Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy...

David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies 13.09.2024 16:17

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guidel...

Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions 09.09.2024 12:49

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing...

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization 09.09.2024 12:35

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better ab...

John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC 09.08.2024 14:38

Please visit answersincme.com/ZVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of metastatic colorectal cancer (mCRC) discusses treatment strategies to enhance patient outcomes during later-line therapy. Upon completion of this activity, participants should be better able to: Identify guideline...

Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer 09.08.2024 18:36

Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this...

Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease 05.08.2024 15:59

Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices fo...

Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice 05.08.2024 13:13

Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis...

Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective 12.07.2024 24:37

Please visit answersincme.com/UYD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatology and digestive oncology discusses guidance for use of TKI therapy in advanced hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Describe evidence for the optimal use of tyr...

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice 12.07.2024 12:10

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should...